ABSTRACT Background: Regeneration of the myocardium and improved ventricular function have been demonstrated in patients with acute myocardial infarction (MI) treated by intracoronary delivery of autologous bone marrow mononuclear cells (BMC) a few days after successful myocardial reperfusion by percutaneous coronary intervention (PCI); however, the effects of intracoronary cell infusion in chronic MI patients are still unknown. Aims: To investigate whether intracoronary infusion of BMC into the infarct-related artery in patients with healed MI could lead to improvement in left ventricular (LV) function. Methods: Among 47 patients with stable ischaemic heart disease due to a previous MI (13 (SD 8) months previously), 24 were randomised to intracoronary infusion of BMC (BMC group) and 23 to a saline infusion (control group) into the target vessel after successful PCI within 12 hours after chest pain occurred. LV systolic and diastolic function, infarct size and myocardial perfusion defect were assessed with the use of echocardiography, magnetic resonance imaging (MRI) or 201 Tl single-photonemission computed tomography (SPECT) at baseline and repeated at the 6-month follow-up examination. Results: BMC treatment did not result in a significant increase in LV ejection fraction in any of the groups by any of the methods used, and the apparent tendency of an improvement was not statistically different between the two groups. The two groups also did not differ significantly in changes of LV end-diastolic and systolic volume, infarct size or myocardial perfusion. However, there was an overall effect of BMC transfer compared with the control group with respect to early/late (E/A) (p,0.001), early diastolic velocity/late diastolic (Aa) velocity (Ea/Aa) ratio (p = 0.002) and isovolumetric relaxation time (p = 0.038) after 6 months, as evaluated by tissue Doppler echocardiography. We noted no complications associated with BMS transfer. Conclusion: Intracoronary transfer of autologous BMC in patients with healed MI did not lead to significant improvement of cardiac systolic function, infarct size or myocardial perfusion, but did lead to improvement in diastolic function.
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Heart failure due to left ventricular (LV) remodelling after myocardial infarction (MI) remains a major cause of morbidity and mortality 1 despite modern reperfusion strategies and advances in pharmacological management. Use of interventional therapeutics (percutaneous coronary intervention, PCI) to recanalise the occluded infarctrelated artery, thereby improving or normalising coronary blood flow, may delay the ventricular remodelling, but cannot preventing or even reverse this process, which represents a major cause of late infarct-related chronic heart failure. 2 3 On the basis of pluripotential cells in the bone marrow capable of further differentiating into endothelium, smooth muscle cells and cardiac myocytes, 4 5 recent experimental and clinical studies have shown that intracoronary transfer of unselected bone marrow mononuclear cells (BMC) in patients with acute MI considerably increases heart function by apparently repairing damaged cells beyond the recovery which occurs with PCI. [6] [7] [8] [9] [10] However, it is currently unknown whether such a treatment strategy may also be feasible in patients with persistent LV dysfunction as a result of healed MI with established scar formation. In this study, we prospectively investigated whether intracoronary infusion of BMC into the infarct-related artery in patients with chronic MI could lead to improvement in LV function.
METHODS

Patients and protocol
The study protocol was performed according to the principles of the Declaration of Helsinki and has been approved by the institutional ethics committee at Zhongshan Hospital, Fudan University, China. All participants provided written informed consent. From October 2004 to December 2005, all hospitalised patients who had had a history of transmural MI and revascularisation plus stent implantation at least 6 months earlier were recruited into the study. The inclusion criteria were age ,75 years, a patent infarct-related artery at the time of stem cell therapy and no coronary bypass surgery. Exclusion criteria were the presence of acutely decompensated heart failure with New York Heart Association (NYHA) class IV, a history of other severe chronic diseases or cancer, or unwillingness to participate. Figure 1 illustrates the study design. Forty-seven eligible patients were randomly assigned to the group that underwent intracoronary infusion of autologous bone marrow mononuclear cells (BMC group; n = 24) or to the control group (CON group, n = 23), in which saline infusion was performed, according to each patient's decision on a signed consent document. All patients underwent conventional echocardiography, cardiac magnetic resonance imaging (MRI) and 201 Ti single-photon-emission computed tomography (SPECT) 24 hours before and 6 months after the procedure. Twenty-four-hour Holter monitoring was performed immediately after transplantation during hospitalisation and at 6-month follow-up. Left heart catheterisation was performed on the day of transplantation and all patients underwent coronary angiography at 6 months after treatment. At the same time, the patient's clinical status, such as symptoms and heart failure classification according to the NYHA criteria, was assessed and a detailed history was taken to document medical procedures and serious adverse events, such as rates of re-hospitalisation for congestive heart failure, re-infarction and death. During the entire study period, all patients were treated according to current practice guidelines with a b-blocker, an angiotensin-converting enzyme (ACE) inhibitor and diuretics.
Cell preparation and administration
On the day of cell therapy, bone marrow (95 (20) ml) was collected under local anaesthesia from the posterior superior iliac spine. BMC were isolated and enriched with the use of Ficoll-Hypaque gradient centrifugation procedures, as previously reported. 7 11 Briefly, bone marrow aspirates were diluted with 0.9% NaCl (1:5) and mononuclear cells were isolated by density gradient centrifugation using Ficoll (Sigma, 800 g 6 25 minutes). Mononuclear cells were washed (800 g 6 5 minutes) three times with phosphate buffered saline and then resuspended in 16 ml of heparin-treated plasma at a density of 2.4 (1.2610 7 cells/ml at room temperature. The placebo solution consisted of 0?9% NaCl containing heparin. Before intracoronary injection, the mononuclear cells were filtered (Falcon) and counted. These cells were used for therapy. All microbiological tests of the clinically used cell preparations proved negative. To ensure that a certain percentage of stem cells were present in the infused mononuclear cells, a 1-ml suspension was subjected to FACS analysis after incubation with anti-human monoclonal antibodies: anti-human CD34 (BD Pharmigen, conjugated with FITC, or CD133 (Miltenyi Biotec) antibodies conjugated with APC. An isotopic serum conjugated to FITC and APC was used as the isotype control. The FACS analysis revealed that 2.4% (0.9%) of BMC was positive for CD34 and 0.75% (0.20%) was positive for CD133.
BMC were administered on the day of preparation. Cell transplantation was performed via the intracoronary administration route as we described previously. 10 An over-the-wire angioplasty balloon catheter was inserted into the stent previously implanted during the acute reperfusion procedure. The balloon was inflated with low pressure (2-4 atm) to completely block blood flow for 2 minutes and repeated five times. During each balloon inflation, 3 ml of BMC suspension were infused distal to the occluding balloon into the infarct-related artery. This manoeuvre prevented backflow of cells and produced stop flow beyond the site of balloon inflation to facilitate high-pressure infiltration of cells into the infarcted zone.
Echocardiograms
Echocardiographic studies were performed by the standard method using a GE Vivid 7 ultrasound system, according to the recommendations of the American Society of Echocardiography. Two-dimensional (2D) images were obtained at mid-papillary and apical levels. LV ejection fraction (LVEF), LV end-diastolic diameters (LVEDd) and LV end-systolic diameters (LVESd) were measured according to Simpson's method. 12 LV diastolic function was evaluated by (tissue) Doppler echocardiography using the following transmitral inflow parameters: transmitral peak early (E), peak late velocities (A), E/A ratio and the E-wave deceleration time (DT, time from peak E velocity to the time when the E wave descent intercepted the zero line). The isovolumetric relaxation time (IVRT; the interval from aortic valve closure to mitral valve opening), transmitral early diastolic (Ea) and late diastolic (Aa) velocities were also measured. Ea/Aa and E/A ratios were calculated for each patient. The measurements were repeated three times, and the average was used for further calculations. Echocardiographic measurements were to be assessed in a research certified core laboratory by specified technicians masked to the treatment assignment.
Cardiac MRI
Patients were studied in the supine position with a 1.5-T clinical scanner (Siemens, Sonata, Germany) equipped with a dedicated cardiac-phased array surface coil. Contrast-enhanced MRI has been widely used to evaluate myocardial injury after MI. A gadolinium-based contrast agent (Gadodiamide; Omniscan, Nycomed Amersham, Bucks, UK) was administered intravenously at a dose of 0.1 mmol per kg body weight, and contrastenhanced images were acquired after a 10-minute delay with the use of an inversion-recovery segmented gradient-echo sequence in long-axis and short-axis planes identical to the cine images.
LV end-diastolic volumes (LVEDV), end-systolic volumes (LVESV) and LVEF were automatically calculated by the software. Infarct size was quantified by selecting the signal intensity threshold of the hyperenhanced area. All studies were processed and evaluated at the MRI core laboratory by an experienced operator who was blinded to the assigned therapy.
Tl-SPECT imaging
All patients underwent a one-day electrocardio-gated stress thallium-201 SPECT imaging protocol 1 day before and Figure 1 Flow chart outlining the study protocol. AMI, acute myocardial infarction; BMCs, bone marrow mononuclear cells; CON, control group; PCI, percutaneous coronary intervention. 6 months after the procedure. All images were acquired using a tri-head SPECT gamma camera (Philips-IRIX; Philips Medical Systems, Milpitas, CA, USA). Myocardial perfusion defects were automatically calculated by software ECTb3.0. All studies were processed and evaluated in the scintigraphic core laboratory by a specified technician who was blinded to the assigned therapy.
Statistical analysis
All data are presented as the mean (SD). Univariate differences between groups were performed with ANOVA for multiple comparisons and Bonferroni's post test. Statistical comparisons between the initial and follow-up data were performed with a paired t test. Comparisons of the changes from baseline to 6 months in the control and treatment groups were made with repeated-measures two-way ANOVA. The ANOVA model included the control versus treatments and baseline versus 6 months as factors, and also included the interaction between the two factors. 
RESULTS
The baseline characteristics of the 47 patients are summarised in table 1. The two groups of patients were well matched. MI had occurred 13 (8) months before entry into the study. Intracoronary application of BMC was performed without any acute or long-term side effects. There was no inflammatory response or myocardial reaction (that is, white blood cell count, C-reactive protein (CRP) and creatinine phosphokinase (CPK)) after cell therapy. No pro-arrhythmic effects were detected on Holter monitoring during follow-up and no deaths or cases with tumours occurred in any of the patients. Restenosis was detected in two patients in the control group and one patient in the BMC group at 6-month follow-up. No significant difference was found in relevant restenosis between the two groups. All patients received guideline medical therapy at baseline and throughout the 6-month follow-up period. Only one patient in the BMC group stopped ACE inhibitor at 1 month after therapy because of cough and changed to ATII blocker. All patients completed 6 months of follow-up. On echocardiography, the mean baseline value among BMC patients was 49.3% (7.2%) for LVEF (p = 0.67) for the comparison with the control group), 54.1 (6.7) mm for LVEDd (p = 0.52) and 36.6 (7.3) mm for LVESd (p = 0.83). At 6 months, LVEF had increased in both groups (3.5% (3.3%) in the BMC group and 2.3% (2.7%) in the control group; p = 0.136). There were no significant differences between groups in the changes in LVEF, LVEDd or LVESd. As measured by MRI, the mean value among BMC patients was 44.3% (5.5%) for LVEF (p = 0.50 for the comparison between the two groups) and 23.6% (4.1%) for infarct size (p = 0.71). There were no significant differences between the two groups in changes in LVEF (2.4% (3.1%) in the BMC group and 1.6% (2.1%) in the control group; p = 0.515) and infarct size (22.3% (1.7%) in the BMC group and 21.6% fig 3) .
The baseline diastolic parameters were comparable between the BMC and control groups. However, at 6 months of followup, the E/A ratio was significantly higher with BMC transplantation compared with no cell infusion (p = 0.009) and IVRT in the BMC group was significantly shorter than that of the control group (p = 0.002).
As shown in figure 4 , compared with the control group, there was an overall effect of BMC transfer on E/A (p,0.001), the Ea/Aa ratios (p = 0.002) and the IVRT (p = 0.038) at 6-month follow-up. Representative tissue Doppler recordings of both groups (at baseline and 6 months) are shown in figure 2 .
One patient in the control group had reinfarction as a result of LAD occlusion distally to the implanted stent. Two patients in the control group and one in BMC group were hospitalised for worsening heart failure. The rate of revascularisation was similar in both groups (table 4) .
DISCUSSION
In this study we examined the effects of intracoronary infusion of adult BMC on LV function in patients with chronic MI (6-36 months). The results demonstrated that infusion of autologous BMC into the patent infarct-related artery did not have a significant beneficial effect on cardiac systolic function and myocardial perfusion at 6 months, but favourably augmented recovery of LV diastolic function compared with the control group.
Despite the recent developments in the treatment of coronary artery disease, heart failure caused by MI still remains a major health problem. The possibility of repairing and growing new myocardium within necrotic tissue as a result of stem cell transplantation or mobilisation has been widely studied in both experimental [13] [14] [15] and clinical conditions. [16] [17] [18] Introduction of stem cells into infarcted myocardium may lessen tissue fibrosis and scar formation by releasing angiogenic factors and initiating cardiac myocyte regeneration, leading to a smaller infarct. 4 19 Although there is still much controversy as to whether infused bone marrow stem cells can differentiate into cardiac myocytes, most current studies of cell transplantation in acute MI got positive results either of improving global, regional LV function, reducing infarct size or increasing myocardial perfusion. Recently, studies by Strauer et al, 20 Assmus et al 21 and Perin et al, 22 also reported beneficial therapeutic effects of stem cell therapy on cardiac performance (a significant improvement in LV function and reduction in infarct size) in chronic MI.
In our study, we performed intracoronary BMC administration in patients with chronic MI (6-36 months) and could not find a significant benefit to cardiac systolic function (including LV regional contractility, see supplementary data on Heart website) and myocardial perfusion at the 6-month follow-up evaluation. However, the recovery of LV diastolic function evaluated by tissue Doppler echocardiography was favourably Figure 3 The E/A ratio at baseline and at 6-month follow-up. The baseline E/A ratio were comparable between the control (CON) and the BMC administration (BMC) group. However, at 6-month follow-up, it increased from 1.0 (0.2) to 1.1 (0.2) in the BMC group and decreased from 1.0 (0.1) to 0.9 (0.1) in the CON group. augmented, compared with the control group. LV diastolic dysfunction, which is associated with a high risk for heart failure, is also a common complication after MI, even if LV systolic function is well preserved. 23 24 Epidemiological studies indicate that up to 40% of cases of heart failure are related to diastolic heart failure. 25 Echocardiography evaluation of diastolic function in the present study was performed by measuring the transmitral flow pattern (E/A), the Ea/Aa, the DT and the IVRT. Our study showed that the ratios of E/A and Ea/Aa decreased significantly and the IVRT was prolonged significantly at the 6-month follow-up examination in the control group when compared with the BMC group, indicating the therapeutic effects of BMC on LV diastolic function. The mechanisms of the benefits are not known. Previous experimental studies in rats indicated that direct intramyocardial injection of BMC 2 months after AMI resulted in obvious improvement in diastolic function and this improvement in diastolic function was associated with reduced LV collagen density. 26 It is possible that the observed improvement of diastolic function evaluated by echocardiography after intracoronary BMC transfer in our study may be related to a reduction in intramyocardial collagen deposition. Indeed, it has been shown by the reports of Kocher et al 26 and Nagaya et al 15 that application of bone marrow angioblasts or mesenchymal stem cells reduced LV collagen deposition in rats after acute myocardial infarction (AMI).
Our main finding was not consistent with the report of Strauer et al 20 (IACT study), which observed a gain of 7% in the LVEF noted in the cell transfer group. There are several possible reasons for this discrepancy. First, the time from MI to cell transplantation was quite different between the two studies. Patients enrolled in our study had a relatively narrow range in the time that had elapsed since the MI (6-36 months), while the patients in the IACT study had a wider time span (5-102 months). Second, only one-vessel disease was included in the IACT study; one-third of our patients had two-vessel or three-vessel disease and the baseline LVEF was 59% in the IACT study versus 46% in this study. Third, perhaps 6 months after treatment is too late to discern a clinical benefit, since studies addressing the effects of BMC in patients with AMI typically cover limited time frames, ranging from 3-6 months. 27 The number of patients and the duration of follow-up were not sufficient to assess whether intracoronary infusion of BMC can reduce the risk of complications and death among patients with heart failure secondary to a previous MI. However, the incidence of individual adverse clinical end points tended to be lower in the BMC group than in the control group (table 4). It is noteworthy that there were no complications immediately or 6 months after cell transplantation; specifically, there were no cardiac arrhythmias or signs of cardiac or systemic inflammation present. We also have not found that stem cell transplantation increases the rate of in-stent restenosis.
Our study had several limitations. No invasive measurements-for example, using a Swan-Ganz catheter of LVdiastolic pressure were performed in the present study. Studies to assess whether improvement of diastolic function is accompanied by a decrease of diastolic pressure after BMC therapy are thus needed. Questions about the underlying mechanisms of the beneficial effects of BMC on diastolic function still should be addressed. Restoration of microvascular function might contribute to the improvement of diastolic function. It has been previously demonstrated that LV-diastolic dysfunction is associated with coronary flow reserve (CFR) impairment and coronary microvascular dysfunction. [28] [29] [30] In the recently published Doppler Substudy of the REPAIR-AMI trial, 17 
Figure 4
Comparison of the changes from baseline to 6-month followup in E/A ratio, Ea/Aa ratio and isovolumetric relaxation time (IVRT) between the control (CON) and the BMC administration group (BMC). BMC therapy significantly increased the E/A ratio (A) and the Ea/Aa (B) ratio and shortened the IVRT (C) when compared with the CON group. 
